EDAP TMS S.A., each representing One Ordinary Share (EDAP) News
Filter EDAP News Items
EDAP News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
EDAP News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest EDAP News From Around the Web
Below are the latest news stories about EDAP TMS SA that investors may wish to consider to help them evaluate EDAP as an investment opportunity.
EDAP Appoints Joshua H. Levine to Board of DirectorsPDF Version AUSTIN, Texas, January 10, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Joshua H. Levine to its Board of Directors. “We are pleased to welcome Josh Levine to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Josh brings a wealth of executive experience and a track record of growing shareholder value by focusing on transformative, high gro |
EDAP Announces First Pancreatic Cancer Patient Treated with Proprietary HIFU TechnologyAUSTIN, Texas, January 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that the first patient has been treated in a phase I/II PULS Trial sponsored by the Centre Léon Bérard, Lyon, France, evaluating proprietary High Intensity Focused Ultrasound (HIFU) technology for the treatment of pancreatic tumors. “The initiation of the PULS Trial represents a major milestone in efforts to develop a new and innovative approach for treating this deva |
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate CancerHIFI Study is the largest (N = 3,328) prospective, comparative, multi-center clinical study ever conducted comparing prostate cancer treatmentsPositive study results are expected to drive further adoption of Focal One as a first line treatment option for the management of localized prostate cancer Study shows Focal One Robotic HIFU is non-inferior to surgery, meeting primary endpoint of non-inferiority for Salvage Treatment-free Survival (STFS) after High Intensity Focused Ultrasounds (HIFU) com |
Senti Bio Appoints Fran Schulz to Board of DirectorsBiotechnology industry executive with a proven track record of advising management teams on corporate and financial strategy for more than 30 yearsSOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Fran Schulz, a highly experienced biotechnolog |
EDAP to Participate in the Piper Sandler 36th Annual Healthcare ConferenceLYON, France, November 27, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced that Ryan Rhodes, Chief Executive Officer of EDAP TMS, is scheduled to participate in a fireside discussion and host 1x1 investor meetings at the upcoming Piper Sandler 36th Annual Healthcare Conference, which is taking place from December 3-5, 2024, in New York City. Presentation Details: Piper Sandler 36th Annual Healthcare Conference Format: Fireside Discussion Date: Tu |
EDAP Announces Scientific Presentation Highlighting Feasibility of Focal One® to Perform Non-thermal Histotripsy Energy Delivery at the 187th Acoustical Society of America MeetingEarly feasibility work demonstrates Focal One system’s ability to generate histotripsy lesions ex vivo LYON, France, November 22, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a scientific presentation which demonstrated the technical feasibility of performing non-thermal histotripsy energy delivery and generating histotripsy lesions in biological tissues ex vivo using the Company’s Focal One® Robotic HIFU technology. The results from the |
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating EndometriosisTreatment with robotic HIFU showed reduction in moderate and severe post-operative complications and reduced hospital stay compared to surgery LYON, France, November 19, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced a moderated scientific presentation of clinical data comparing Focal One HIFU versus surgery for the treatment of deep infiltrating endometriosis at the 2024 AAGL Global Congress, which took place from November 16-19, 2024, in |
EDAP TMS Third Quarter 2024 Earnings: Misses ExpectationsEDAP TMS ( NASDAQ:EDAP ) Third Quarter 2024 Results Key Financial Results Revenue: €13.1m (up 12% from 3Q 2023). Net... |
Edap TMS SA (EDAP) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amidst Rising ExpensesEdap TMS SA (EDAP) reports strong revenue growth driven by HIFU technology, despite increased operating expenses and a widened net loss. |
EDAP Reports Third Quarter 2024 Financial ResultsReported Q3 worldwide revenue of EUR 13.1 million (USD 14.4 million), increasing 11.6% over Q3 2023Reported Q3 worldwide HIFU revenue of EUR 4.5 million (USD 4.9 million), increasing 48.2% over Q3 202334% year-over-year growth in U.S. Focal One HIFU procedures CMS increases Medicare Hospital Outpatient Focal One HIFU procedure payment by 5.4% for 2025Announced AI collaboration with Avenda Health for Focal One Robotic HIFUCompany to host conference call and webcast today, November 7th, at 8:30 a. |